EGFR and colorectal carcinoma: As a leader in CRC drug resistance research, professor Bardelli A focused on the molecular mechanisms and pharmacological efficacy of targeted drug resistance in CRC, especially anti-epidermal growth factor receptor (EGFR) drugs such as cetuximab and panitumumab.